Abstract

Greater emphasis has been placed on advancing proteomics studies from discovery and/or relative quantitation to validated quantitative methods in an effort to establish clinical assays. The typical workflow involves first performing discovery based experiments to identify protein expression levels that are confidently changing between a control and treated samples and generate product ion information used to sequence the precursor peptide. The difficulty arises in transferring discovery based methods directly over to validated quantitation methods since each is generally performed on separate mass spectral platforms. Low confidence has been placed on relating relative product ion abundance obtained from ion trap CID to that observed using a triple quadrupole mass spectrometer due to the difference in ion activation mechanisms and the timescale of the excitation. Thus, the only information transferred from one method to the other is protein id, peptide sequence, and the most abundant charge state resulting in further method development to complete the SRM assay. Common approaches to determine SRM transitions are based on a set of accepted rules to determine the best possible ion pair(s), which are then searched against the matrix database to determine the uniqueness of each mass pair. We contend that the relative abundance of product ions originating from ion trap CID can be a used to directly assign the most sensitive ion pairs for the targeted SRM methods.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call